drugset / Trial / NCT05636436
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Phase 1
Active not recruiting
132 enrolled
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.
Timeline
- Start
- 2022-12-07
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MA105 | Unknown | 0.5 ml | Intramuscular |
| Subject | Recombinant Herpes Zoster Vaccine (CHO cells) | Vaccine | 50 ug | Intramuscular |
| Subject | Recombinant Herpes Zoster Vaccine (CHO cells) | Vaccine | 0.5 ml | Intramuscular |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | 50 ug | Intramuscular |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | 0.5 ml | Intramuscular |